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Bromodomain-containing protein 7 (BRD7) is amem-
ber of the bromodomain-containing protein family
that is known to play a role as tumor suppressors.
Here, we show that BRD7 is a component of the
unfolded protein response (UPR) signaling through
its ability to regulate X-box binding protein 1 (XBP1)
nuclear translocation. BRD7 interacts with the regu-
latory subunits of phosphatidylinositol 3-kinase
(PI3K) and increases the nuclear translocation of
both p85a and p85b and the spliced form of XBP1
(XBP1s). Deficiency of BRD7 blocks the nuclear
translocation of XBP1s. Furthermore, our in vivo
studies have shown that BRD7 protein levels are
reduced in the liver of obese mice, and reinstating
BRD7 levels in the liver restores XBP1s nuclear
translocation, improves glucose homeostasis, and
ultimately reduces the blood glucose levels in the
obese and diabetic mouse models.
INTRODUCTION
Obesity is a fast-growing global health problem and the leading
cause for the development of type 2 diabetes, nonalcoholic stea-
tohepatitis, and cardiovascular disease (Hevener and Febbraio,
2010; Kahn and Flier, 2000; Muoio and Newgard, 2006; Qatanani
and Lazar, 2007; Sun and Karin, 2012). Increased insulin resis-
tance and perturbed glucose tolerance in obesity are the main
underlying pathologies for the development of type 2 diabetes
(Guilherme et al., 2008; Kadowaki et al., 2003; Ko¨nner and
Bru¨ning, 2012). The majority of patients diagnosed with type 2
diabetes are obese (de Luca and Olefsky, 2006; Kitamura and
Accili, 2004). Despite enormous efforts, the molecular mecha-
nisms of obesity-induced insulin resistance and glucose intoler-
ance remain incompletely understood. Therefore, understanding
the molecular links between obesity, insulin resistance, and type
2 diabetes is of crucial importance for the development of new
therapeutic strategies.The endoplasmic reticulum (ER) is a cellular organelle in which
secretory and membrane-bound proteins are folded into their
three-dimensional structures and lipids and sterols are synthe-
sized (Palade, 1956). Certain conditions, such as nutrient depri-
vation, increased protein trafficking, exposure to free fatty acids,
accumulation of unfolded or misfolded proteins in the lumen of
ER, and alterations in calcium homeostasis, interfere with proper
function of the ER (Fonseca et al., 2011; Park et al., 2010b;
Schro¨der and Kaufman, 2005; Walter and Ron, 2011). Perturba-
tions in ER homeostasis can create a condition defined as ER
stress (Park and Ozcan, 2013; Ron and Walter, 2007; Schro¨der
and Kaufman, 2005; Walter and Ron, 2011). ER stress activates
a cascade of complex signaling networks, collectively referred
to as unfolded protein response (UPR) (Marciniak and Ron,
2006; Park and Ozcan, 2013; Schro¨der and Kaufman, 2005;
Walter and Ron, 2011; Wang and Kaufman, 2012). The UPR
is initiated by PKR-like endoplasmic reticulum kinase (PERK),
inositol-requiring enzyme 1 (IRE1), and activating transcription
factor 6 (ATF6).
IRE1 has kinase and endoribonuclease activities. Upon activa-
tion, the endoribonuclease domain of IRE1 cleaves the mRNA of
a transcription factor called X-box binding protein 1 (XBP1) and
removes a 26 bp intron, resulting in a higher molecular weight
protein called the spliced form of XBP1 (XBP1s) (Calfon et al.,
2002; Lee et al., 2002; Yoshida et al., 2001). While the main func-
tion of XBP1s is to increase the folding capacity of the ER, it also
regulates components in the ER-associated degradation (ERAD)
pathway (Bernales et al., 2006; Lee et al., 2003; Merksamer and
Papa, 2010; Ron and Walter, 2007; Zhang and Kaufman, 2008).
Over the last decade, we and others have shown that obesity
leads to the development of ER stress in the liver, brain, and ad-
ipose tissues (Nakatani et al., 2005; Ozawa et al., 2005; Ozcan
et al., 2004, 2006, 2008, 2009), which in turn contributes to the
development of insulin resistance and type 2 diabetes. Previous
observations have shown that genetic ablation of even one allele
of XBP1 is sufficient to create insulin resistance and type 2
diabetes (Ozcan et al., 2004). We have recently demonstrated
that reduced XBP1s activity in obesity plays a crucial role in
the development of insulin resistance and type 2 diabetes (Lee
et al., 2011; Park et al., 2010a; Zhou et al., 2011). Consistent
with this notion, reinstating the activity of XBP1s in the liver of
severely obese and diabetic mice reduced blood glucose levelsCell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc. 73
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2011).
We previously have reported that XBP1s interacts with the
regulatory subunits of the class IA phosphatidylinositol 3-kinase
(PI3K), p85a and p85b (Park et al., 2010a; Winnay et al., 2010),
which is one of the main nodules in insulin signaling. The interac-
tion between p85s and XBP1s is a prerequisite for the nuclear
translocation of XBP1s (Park et al., 2010a). More importantly,
we showed that disruption of the interaction between p85s and
XBP1s is a major cause for the development of insulin resistance
in obesity (Park et al., 2010a).
Bromodomain-containing protein 7 (BRD7) is a subunit
of the polybromo-associated BRG1-associated factor (PBAF)
complex, with a molecular weight of about 75 kDa (Kaeser
et al., 2008). It plays a role in transcriptional regulation by binding
to acetylated histone through its bromodomain (Peng et al.,
2006). It was shown that the expression level of BRD7 is signifi-
cantly decreased in nasopharyngeal carcinoma (NPC) biopsies
(Zhou et al., 2004). Furthermore, BRD7 was reported to partici-
pate in tumor suppression, cell cycle, and cell growth (Kaeser
et al., 2008; Peng et al., 2007; Zhou et al., 2004). Recent work
suggested that BRD7 binds to BRCA-1 and p53 and acts as a
tumor suppressor (Burrows et al., 2010; Drost et al., 2010; Harte
et al., 2010; Mantovani et al., 2010).
Chiu et al. (2014) recently showed that BRD7 binds to p85a
and increases its nuclear translocation. Considering the effect
of p85s on XBP1s nuclear translocation (Park et al., 2010a), we
investigated whether BRD7 plays a role in regulation of XBP1s,
ER stress, and glucose metabolism.
RESULTS
BRD7 Interacts with p85a and Increases Its Nuclear
Translocation
To confirm the interaction between BRD7 and the regulatory
subunit of PI3K, p85a (Chiu et al., 2014), we expressed mouse
BRD7 and p85a by infecting the human embryonic kidney
293 (HEK293) cells with adenoviruses that express BRD7 (Ad-
BRD7) and flag-tagged p85a (Ad-p85a-flag). Subsequently, we
immunoprecipitated p85a using an antibody against flag, blotted
the precipitate with an antibody specific for BRD7, and docu-
mented that BRD7 exists in p85a immunoprecipitates (Fig-
ure 1A). This result indicates that BRD7 and p85a interact. We
also performed reverse immunoprecipitation, in which BRD7
was pulled down and the existence of p85a in the precipitates
was examined. Results from this experiment confirmed the inter-
action of these two proteins (Figure 1B). Next, we investigated
whether BRD7 modulates the nuclear migration of p85a. We
infected HEK293 cells with increasing doses of Ad-BRD7 while
keeping the expression of p85a constant and then analyzed
p85a levels in the nuclear fractions. Increasing the expression
level of BRD7 led to a higher translocation of p85a to the nucleus
(Figure 1C). We also tested whether BRD7 can increase the
nuclear translocation of p85b by infecting HEK293 cells with
increasing doses of Ad-BRD7 while keeping the expression of
p85b constant. BRD7 led to increased nuclear translocation of
p85b as well (Figure S1A available online).
These observations prompted us to investigate whether BRD7
has any effect on XBP1s, because we have previously shown74 Cell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc.that p85a/p85b binds to XBP1s and increases its nuclear
translocation (Park et al., 2010a). For this purpose, we infected
HEK293 cells with XBP1s-expressing adenovirus (Ad-XBP1s)
at a constant dose along with incremental doses of Ad-BRD7.
Indeed, we found that upregulating BRD7 level increases the
nuclear translocation of XBP1s (Figure 1D) without increasing
XBP1 mRNA levels (data not shown).
The next question we asked was how BRD7 increases the
XBP1s nuclear translocation.We exploredwhether it is mediated
through a direct interaction of BRD7 with XBP1s that is indepen-
dent of p85a or through the ability of BRD7 to regulate p85a and
consequent XBP1s interaction. We first expressed BRD7 and
XBP1s in HEK293 cells by infecting the cells with Ad-BRD7
and Ad-XBP1s and performed XBP1 immunoprecipitation. We
blotted the precipitate with an antibody that is specific for
BRD7 and showed that BRD7 and XBP1s can be coimmunopre-
cipitated (Figure 1E), indicating that these two proteins either
directly interact or exist in the same protein complex. Consid-
ering the fact that both BRD7 and p85a can be immunoprecipi-
tated with XBP1s (Park et al., 2010a), we asked whether BRD7
could directly bind to XBP1s in the absence of p85a/p85b.
Thus, we knocked down p85a and p85b in mouse embryonic
fibroblasts (MEFs) with an shRNA lentivirus system specific for
p85a and p85b to create p85a/p85b/ double knockdown
(DKD) cell line. We also created a control cell line, PLKO, using
an empty lentivirus (Figure 1F). The interaction between BRD7
and XBP1s was observed in control PLKO cells (Figure 1F).
However, this interaction was reduced in p85a/p85b-depleted
DKD cells (Figure 1F). After obtaining these results, we investi-
gated the nature of the interaction between BRD7 and XBP1s
in p85a/p85b double knockout (DKO) cells. Following expression
of BRD7 and XBP1s in p85a/p85b DKO cells, we performed
XBP1s immunoprecipitation and investigated the presence
of BRD7 in these precipitates. The interaction between BRD7
and XBP1s was not detected at all in p85a/p85b DKO cells
(Figure 1G), indicating that the presence of p85a or p85b is
necessary for BRD7-XBP1s interaction.
Since our results have shown that BRD7 interacts with XBP1s
only in the presence of p85a/p85b, we then askedwhether BRD7
is still capable of increasing the nuclear translocation of XBP1s in
the absence of p85a/p85b. For this purpose, we infected the
DKD and their control cells with Ad-XBP1s at a constant dose
and increasing doses of Ad-BRD7. We found that BRD7 could
not increase transport of XBP1s to the nucleus in DKD cells as
it did in PLKO cells (Figure 1H). Moreover, XBP1s was not de-
tected in the nucleus of DKO cells even with overexpression of
BRD7 (Figure 1I), indicating that the presence of p85a/p85b is
required for BRD7 to force XBP1s to the nucleus.
BRD7 and p85a Are Required for the Activity of XBP1s
The above findings indicate that BRD7 plays a role in XBP1s’
nuclear migration. To further investigate the nature of the inter-
action between p85a, XBP1s, and BRD7, we expressed p85a
and XBP1s in HEK293 cells either with or without BRD7 (Fig-
ure 2A). Subsequently, we isolated the cytoplasmic and nuclear
fractions and performed XBP1s immunoprecipitation from both
compartments. BRD7 expression reduced the amount of
p85a-XBP1s complex in the cytoplasm (Figure 2A, left panel).
However, it increased the nuclear amount of p85a-XBP1s
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Figure 1. BRD7 Binds to p85a and Increases Its Nuclear Translocation
(A) Immunoblotting for BRD7 and flag-tagged p85a proteins after immunoprecipitation of p85a from HEK293 cells that were infected with Ad-BRD7 alone,
Ad-p85a-flag alone, or Ad-BRD7 and Ad-p85a-flag. Total lysates were immunoblotted for BRD7 and tubulin.
(B) Immunoblots of flag-p85a and BRD7 after BRD7 immunoprecipitation from HEK293 cells that were infected with the indicated adenoviruses.
(C) Nuclear protein levels of p85a in HEK293 cells infected with increasing doses of Ad-BRD7 and a constant dose of Ad-p85a-flag. Lamin A/C was used as a
control for nuclear protein level.
(D) Nuclear protein levels of XBP1s in HEK293 cells infected with increasing doses of Ad-BRD7 and a constant dose of XBP1s.
(E) Immunoblotting for BRD7 and XBP1s following immunoprecipitation with XBP1-specific antibody. Total protein levels of BRD7 and tubulin are shown below.
(F) BRD7 immunoblotting after XBP1 immunoprecipitation from DKD (p85a and p85b double knockdown) and PLKO (control) cells that were infected with
Ad-BRD7 and Ad-XBP1s. Total protein amounts of p85s, BRD7, XBP1s, and tubulin are shown below.
(G) Immunoblotting for BRD7 protein after XBP1 immunoprecipitation from DKO (p85a and p85b double knockout) and its control cells that were infected with
Ad-BRD7 and Ad-XBP1s. Total protein amounts of p85s, BRD7, XBP1, and tubulin are shown below.
(H) Nuclear protein amounts of XBP1s in PLKO and DKD cells infected with increasing doses of Ad-BRD7 and a constant dose of XBP1s. NUP98 was used as a
control for nuclear protein level.
(I) Western blot for XBP1s in DKO cells and its control cells infected with Ad-BRD7 and Ad-XBP1s. Lamin A/C was used as a control. Each experiment was
independently repeated three times.
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BRD7 enhances the binding of p85 to XBP1s and increases its
nuclear translocation.
We previously have shown that p85a and p85b form a hetero-
dimer, which can be disrupted by insulin treatment (Park et al.,
2010a). We have reported that insulin promotes the nuclear
translocation of XBP1s by increasing the binding of p85a/p85b
monomers to XBP1s (Park et al., 2010a). Considering this
data, we investigated whether insulin regulates the BRD7-
p85-XBP1s complex. First, we expressed p85a and BRD7 in
HEK293 cells by infecting with Ad-BRD7 and Ad-p85a-flag.
Following serum starvation, we stimulated the cells with insulin
(500 nM) for various time points. Subsequently, we immunopre-
cipitated p85a with an antibody against flag and immunoblotted
for BRD7 to investigate whether the interaction between p85a
and BRD7 is affected by insulin treatment. The results showed
that insulin enhances the association of p85a and BRD7 in the
nuclear fractions (Figure 2B). We then investigated the effect of
insulin on the formation of the BRD7-p85a-XBP1s complex.We infected HEK293 cells with Ad-BRD7 and Ad-XBP1s-flag,
and following an overnight serum deprivation, we stimulated
the cells with insulin (500 nM) for 0.5 and 2 hr. XBP1 was then
immunoprecipitated, and the immunoprecipitates were blotted
for BRD7. Insulin led to increased binding of BRD7 to XBP1s in
the nucleus (Figure 2C).
To further understand how BRD7 is regulated, we infected
HEK293 cells with increasing doses of Ad-BRD7 and a constant
dose of Ad-p85a-flag and Ad-p85b-myc and then immuno-
precipitated p85a using an antibody against flag, followed by
western blot using antibody against myc to analyze whether
the association between p85a and p85b is affected by BRD7
expression. These results showed that increasing BRD7 expres-
sion disrupts the p85a/p85b heterodimer (Figure 2D).
We next examined whether BRD7’s ability to increase nuclear
translocation of XBP1s also has positive modulatory effects on
XBP1s activity. For this purpose, we expressed BRD7 in MEFs
and analyzed the mRNA levels of various genes that are the tar-
gets of XBP1s, such as endoplasmic reticulum-localized DnaJCell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc. 75
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Figure 2. BRD7 Increases the Nuclear Translocation of XBP1s
(A) Flag-p85a and flag-XBP1s immunoblots after XBP1 immunoprecipitation from cytoplasmic and nuclear protein fractions of HEK293 cells that were infected
with Ad-p85a-flag and Ad-XBP1s-flag without or with Ad-BRD7. Total lysates were immunoblotted for BRD7 and p85a. NUP98 and tubulin were used as controls
for nuclear and cytoplasmic protein levels, respectively.
(B) BRD7 and flag-p85a immunoblots after flag immunoprecipitation from cytoplasmic and nuclear protein fractions of HEK293 cells that were infected with
Ad-p85a-flag and Ad-BRD7, followed by insulin treatment at 500 nM for indicated times. Each cytoplasmic and nuclear protein lysate was immunoblotted for
BRD7, flag, and tubulin or NUP98.
(C) BRD7 immunoblotting in XBP1 immunoprecipitates after insulin (500 nM) stimulation. Protein lysates were immunoblotted for the indicated antibodies.
(D) Nuclear protein amounts of p85a and p85b in HEK293 cells infectedwith a constant dose of Ad-85a-flag and Ad-p85b-myc and increasing doses of Ad-BRD7.
(E) Expression levels of XBP1 target genes, Erdj4, Herp, and Ero1a, in MEFs infected with Ad-LacZ or Ad-BRD7.
(F) Western blot analysis for nuclear XBP1s proteins in HEK293 cells that were infected with the indicated adenoviruses.
(G–I) Male wild-type mice (8 weeks old) were injected with Ad-LacZ shRNA or Ad-BRD7 shRNA (1.5 3 108 pfu/g, n = 6 for each group) through the tail vein.
(G) Nuclear XBP1s protein amounts at 24 hr of fasting and during 1 hr of refeeding on day 7 postinjection (left). NUP98 was used as a control. Quantification of the
western blot showing the ratio of XBP1s toNUP98 (right). Each experimentwas independently repeated three times, except for in (G)–(I). Animal experimentswere
repeated in two independent cohorts.
(legend continued on next page)
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BRD7 Improves Glucose Homeostasishomologs (Erdj4), homocysteine-inducible, endoplasmic reticu-
lum stress-inducible, ubiquitin-like domain member 1 (Herpud1;
Herp), and endoplasmic reticulum oxidoreductin 1a (Ero1a).
Quantitative PCR (qPCR) analysis showed that expression of
BRD7 significantly upregulated the transcription of Erdj4, Herp,
and Ero1a (Figure 2E), suggesting that BRD7 increases the activ-
ity of XBP1s as a transcription factor in the nucleus.
In order to address whether BRD7 is required in the nuclear
translocation process of XBP1s, we first identified an shRNA
sequence that is specific for BRD7 mRNA, showed the efficacy
of this shRNA, and then cloned this sequence into an adenovirus
vector (Ad-BRD7 shRNA). Infections of MEFs led to a highly sig-
nificant reduction in BRD7mRNA and protein levels (Figures S2A
and S2B). Subsequently, we investigated the nuclear migration
pattern of XBP1s in the absence of BRD7. We expressed BRD7
shRNA along with XBP1s in HEK293 cells. There was a major
reduction in the nuclear XBP1s levels in BRD7-depleted cells
when compared to the control cells or cells overexpressing
BRD7 (Figure 2F). To further confirm this result in vivo,we injected
8-week-old male lean mice with 1.5 3 108 plaque-forming units
(pfu)/g of Ad-BRD7 shRNA or Ad-LacZ shRNA via the tail vein.
We previously reported that fasting wild-type mice for 24 hr and
refeeding food ad libitum for 1 hr markedly increases the XBP1
splicing and nuclear translocation of XBP1s (Park et al., 2010a).
This increased nuclear translocation of XBP1s with refeeding
was also observed in the mice that were injected with Ad-LacZ
shRNA, but to a comparably lesser extent in the mice that were
injected with Ad-BRD7 shRNA (Figure 2G), without any change
in the splicing of XBP1 mRNA (Figure 2H). This suggests that
reduced nuclear XBP1s levels in the liver of Ad-BRD7 shRNA-in-
jectedmice are not due to a defect in XBP1 splicing. In parallel to
these results, expression of XBP1 target genes was reduced,
while expression of CHOP was increased in the liver of the Ad-
BRD7 shRNA-injected group when compared to those that
were injected with Ad-LacZ shRNA (Figure 2I).
BRD7 Overexpression in the Liver of ob/ob Mice
Establishes Euglycemia
Considering the defect in hepatic XBP1s nuclear translocation in
obese mice as well as our in vitro results that show that BRD7 is
involved in the regulation of XBP1s nuclear migration and activ-
ity, we investigated whether BRD7 levels are reduced in the liver
of obese mice. Indeed, we found that there was a significant
reduction in the BRD7 protein levels in the liver of ob/ob mice
when compared with the lean controls (Figure 3A). Furthermore,
we showed that BRD7 mRNA levels were increased during the
refeeding period in wild-type mice, but this increment was lost
in ob/ob mice (Figure 3B).
Obesity is a condition of hyperinsulinemia and elevated ER
stress. Therefore, we sought to investigate whether prolonged
insulin stimulation or ER stress is a cause of the reduced BRD7
expression level in obesity. For this purpose, we first induced
ER stress in MEFs by treating the cells with tunicamycin at
various doses (0.1–10 mg/ml) for 1 hr following overnight starva-(H) XBP1 mRNA splicing assay in Ad-LacZ shRNA- or Ad-BRD7 shRNA-injected
(I) Relative mRNA levels of Erdj4, Herp, and CHOP in the liver of Ad-LacZ sh
represented as mean ± SEM; p values were determined by Student’s t test. *p <
three times.tion and analyzed the endogenous BRD7 protein and mRNA
levels by performing western blot and qPCR, respectively. The
results showed no significant difference in BRD7 expression
levels after tunicamycin treatment (Figures S3A and S3B). In
addition, we treated MEFs and Fao cells with tunicamycin at
a concentration of 3 mg/ml for 1, 2, and 3 hr. The treatment
of the cells with tunicamycin did not alter BRD7 expression pat-
terns either (Figures S3C–S3F). Next, after overnight starvation,
we stimulated Fao and HEK293 cells with insulin (500 nM) for
different time points. Exposure of the cells to insulin did not affect
BRD7 gene expression levels (Figures S3G–S3I).
We previously have reported that overexpression of p85a
or p85b in the liver of obese and diabetic mice reinstates the
nuclear translocation of XBP1s, reduces ER stress, improves
glucose tolerance, and ultimately reduces the blood glucose
levels (Park et al., 2010a). Given that BRD7 has the ability to
increase the nuclear translocation of both p85a/p85b and
XBP1s, and that its expression is significantly reduced in the liver
of obese mice, we hypothesized that upregulating the expres-
sion of BRD7 in the liver of obese and diabetic mice would
improve glucose tolerance and reduce blood glucose levels.
To test this hypothesis, we overexpressed BRD7 in the liver of
ob/ob mice by tail vein injection of Ad-BRD7 and Ad-LacZ as a
control at a dose of 1 3 108 pfu/g (Figures S3J and S3K). After
3 days of injection, we fasted the mice for 6 hr and measured
the basal blood glucose levels. The Ad-BRD7-injected group
had significantly lower blood glucose levels than those in the
Ad-LacZ-injected group (Figure 3C). There was no difference in
the body weight or the food intake between Ad-BRD7- and
Ad-LacZ-injected groups (Figures S3L and S3M). Glucose toler-
ance test (GTT) was performed at day 5 postinjection, and the
result revealed a major improvement in the glucose disposal
rate in the Ad-BRD7-injected group (Figure 3D). Insulin tolerance
test (ITT) at day 7 showed that whole-body insulin sensitivity was
improved (Figure 3E).
Next, we investigated whether hepatic insulin receptor
signaling is altered after BRD7 expression in the ob/ob mice.
To do this, we infused either insulin (0.35 IU/kg) or saline through
the portal vein into the liver of ob/obmice on postinjection day 8.
The phospho/total insulin receptor (IR) and insulin receptor sub-
strate 1 (IRS1) values were slightly increased, but did not reach
significant levels in the Ad-BRD7-injected group (Figure 3F).
However, AktThr308 and AktSer473 phosphorylations were signifi-
cantly increased (Figure 3F). These results indicate that BRD7
expression in the liver leads to an increase in the sensitivity of
IRS1-Akt axes of the IR signaling cascade.
Furthermore, to investigate whether BRD7 overexpression in-
creases the association of p85 with IRS proteins, we performed
p85 immunoprecipitation from the liver tissues that were infused
with insulin or saline and then immunoblotted for IRS1 and IRS2.
The results showed that the interaction between p85s and IRSs
is indeed increased after insulin stimulation in the Ad-BRD7-
injected group (Figure 3G) when compared to those of the Ad-
LacZ-injected group.mice at 24 hr of fasting and 1 hr after refeeding.
RNA- or Ad-BRD7 shRNA-injected mice after 6 hr of fasting. Error bars are
0.05, **p < 0.01, ***p < 0.001. Each experiment was independently repeated
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Figure 3. Restoration of BRD7 in the Liver of ob/ob Mice Improves Glucose Tolerance and Establishes Euglycemia
(A) Total BRD7 protein amounts in the liver of lean wild-type and ob/obmice at 6 hr of fasting (top). Quantification of the western blot showing the ratio of BRD7 to
tubulin (bottom).
(B) BRD7 mRNA levels in the wild-type and ob/ob mouse livers during 24 hr of fasting and 1 and 3 hr of refeeding states.
(C–G) Male ob/ob mice (8 weeks old) were injected with Ad-BRD7 or Ad-LacZ (1 3 108 pfu/g, n = 6 for each group) as a control through the tail vein.
(C) Blood glucose levels (mg/dl) after 6 hr fasting on day 3 of the injections.
(D) Glucose tolerance test (GTT) on day 5 postinjection (left). Area under the curve of GTT (right).
(E) Insulin tolerance test (ITT) on day 7 postinjection (left). Area under the curve of ITT (right).
(F) In vivo insulin receptor signaling in the liver of Ad-LacZ- orAd-BRD7-injectedob/obmiceonday 8 after injection (left). Quantifications of thewestern blots (right).
(G) Immunoblots of IRS1, IRS2, and p85 after p85 immunoprecipitation of the liver tissues that were infused with insulin in Ad-LacZ- and Ad-BRD7-injected ob/ob
mice (left). Quantifications of the western blots (right). Error bars are represented as mean ± SEM; p values in (B) and (C) were determined by Student’s t test.
Significance in (D) and (E) was determined by two-way ANOVA with the Bonferroni multiple-comparison analysis. *p < 0.05, **p < 0.01, ***p < 0.001. Experiments
were repeated in three independent cohorts.
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Figure 4. Restoration of BRD7 in the Liver of ob/ob Mice Releases ER Stress and Displays Improved Phenotypes
Male ob/ob mice (8 weeks old) were injected with Ad-BRD7 or Ad-LacZ (1 3 108 pfu/g, n = 6 for each group) as a control through the tail vein.
(A) Western blots for nuclear XBP1s protein on day 8 postinjection (top). Quantification of the western blot showing the ratio of BRD7 to tubulin (bottom).
(B and C) mRNA and protein levels of XBP1s target genes in the liver of Ad-LacZ- and Ad-BRD7-injected mice after 6 hr of fasting were analyzed by qPCR (B) and
western blot (C) (left). Quantifications of the western blots are shown to the right in (C).
(D) PERK phosphorylation on Thr980, total PERK, eIF2a phosphorylation on Ser51, and total eIF2a protein levels in the liver of Ad-LacZ- and Ad-BRD7-injected
ob/ob mice were analyzed by western blot.
(E) Total and nuclear amounts of FoxO1 protein in the liver of Ad-LacZ- or Ad-BRD7-injected ob/ob mice.
(F) Relative mRNA levels of G6p, Fbp, and Pepck.
(G) Macroscopic view of the liver of Ad-LacZ-injected (top) and Ad-BRD7-injected (bottom) ob/ob mice.
(H) H&E staining of liver sections in 43 (left) and 103 (right) magnifications.
(I) Triglyceride contents (mg/g) in the liver.
(J) RelativemRNA levels ofAcc1, FasN, andDgat2. Error bars are represented asmean ± SEM; p values were determined by Student’s t test. *p < 0.05, **p < 0.01,
***p < 0.001. Experiments were repeated in three independent cohorts.
Cell Metabolism
BRD7 Improves Glucose HomeostasisNext, we sought to investigate whether an increase in BRD7
expression leads to increased XBP1s nuclear translocation and
a corresponding upregulation of XBP1s target genes in in vivo
settings. For this purpose, we injected 8-week-old male ob/ob
mice with Ad-BRD7 and Ad-LacZ at a dose of 1 3 108 pfu/g
through the tail vein. The overexpression of Ad-BRD7 in the liver
of ob/ob mice greatly increased XBP1s nuclear translocation
(12-fold upregulation; Figure 4A). In line with the increased
nuclear translocation of XBP1s, target gene expression, such
as that of Erdj4, Herp, and Ero1a, was significantly upregulated
at both mRNA and protein levels (Figures 4B and 4C).
In parallel, we observed decreased PERK phosphorylation in
Ad-BRD7-injected ob/ob mouse livers when compared to that
in the Ad-LacZ-injected group (Figures 4D and S4A). Accord-ingly, the levels of phospho-eIF2aSer51, a direct downstream
target of phospho-PERK, were also decreased (Figures 4D and
S4B). These results indicate that ER stress is reduced after
BRD7 overexpression in the liver of ob/ob mice. Considering
our previously published results showing that XBP1s leads to
FoxO1 degradation (Zhou et al., 2011), we investigated the nu-
clear and total levels of FoxO1. BRD7 overexpression led to a
major decrease in both nuclear and total FoxO1 levels in the liver
of ob/ob mice (Figure 4E). Accordingly, gene expressions of
glucose-6-phosphatase (G6P), fructose bisphosphatase (FbP),
and phosphoenolpyruvate carboxykinase (Pepck) were signifi-
cantly reduced in BRD7-overexpressingmouse livers (Figure 4F).
Furthermore, even macroscopically, BRD7-overexpressing
livers had a healthier appearance than the Ad-LacZ-injectedCell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc. 79
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of the sections from the liver of Ad-LacZ- and Ad-BRD7-injected
ob/ob mice showed a major decrease in the lipid droplets
(Figure 4H). In line with these observations, analysis of liver tri-
glyceride (TG; mg/dl) content showed a significant reduction in
the livers of Ad-BRD7-injected ob/ob mice (Figure 4I). Analysis
of lipogenic gene expressions, such as acetyl coenzyme A
(acetyl-CoA) carboxylase 1 (Acc1), fatty acid synthase (FasN),
and diacylglycerol acyltransferase 2 (Dgat2), were significantly
reduced in BRD7-overexpressing mouse livers (Figure 4J).
Taken together, these results indicate that BRD7 also has antili-
pogenic properties.
Restoration of BRD7 in the Liver of DIO Mice Improves
Glucose Metabolism
Our data thus far showed that BRD7 protein levels are reduced in
genetically obese and diabetic ob/ob mice and that restoration
of BRD7 levels reestablishes glucose homeostasis. Next, we
sought to examine the BRD7 expression levels in diet-induced
obese (DIO) mouse models. For this purpose, wild-type lean
C57BL/6 male mice were placed on either high-fat diet (HFD,
45% kcal from fat) or normal chow diet (NCD) feeding soon after
weaning at the age of 3.5weeks andmaintained on the same diet
for 16 weeks. At the end of the 16-week feeding period, we
examined the protein levels of BRD7 in the liver of HFD- and
NCD-fed groups. We observed a marked reduction in the hepat-
ic level of BRD7 in the HFD-fed mice (Figure 5A). We then
compared the BRD7 protein levels among wild-type mice on
NCD, genetically obese ob/ob mice, and wild-type mice that
were kept on HFD for 8 weeks. The expression levels of BRD7
in the liver of 8-week-old HFD-fed mice were also significantly
reduced, and this reduction was comparable to that seen
in ob/ob mice (Figure 5B). Next, we overexpressed BRD7 or
LacZ (as a control) in the liver of mice that were fed either NCD
or HFD for 8 weeks by tail vein injection of the corresponding ad-
enoviruses at a dose of 5 3 107 pfu/g. After 3 days of injection,
we measured the blood glucose levels and showed that the
blood glucose levels of the Ad-BRD7-injected group were signif-
icantly lower compared to those of the Ad-LacZ-injected group
(Figure 5C). GTT was performed at day 5 postinjection, and the
result revealed a significant improvement in the glucose disposal
rate in the Ad-BRD7-injected group (Figure 5D). In addition, the
overexpression of BRD7 in the liver of the HFD mouse group
restored the ability of XBP1s to translocate to the nucleus, while
the Ad-LacZ-injected mouse group could not translocate XBP1s
to the nucleus (Figure 5E). Next, we fasted these two groups for
24 hr and then gave them food ad libitum for 1 hr. We collected
the liver and determined gene expression profiles of XBP1s
target genes. Refeeding led to significantly higher mRNA levels
of Erdj4, Herp, and Ero1a in the Ad-BRD7-injected group
compared to the Ad-LacZ group (Figures 5F–5H), indicating
that BRD7, as seen in genetically obese models, also increases
XBP1s activity in the HFD-fed obese mice.
DISCUSSION
Over the last decade, XBP1s has emerged as a central player in
the maintenance of glucose homeostasis due to its ability to
reduce ER stress, increase insulin sensitivity, and also degrade80 Cell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc.FoxO1 through a direct protein interaction (Lee et al., 2011;
Ozcan et al., 2004; Park et al., 2010a; Zhou et al., 2011). Reduced
XBP1s activity in obesity due to impaired nuclear translocation
is a major cause of the development of ER stress and, conse-
quently, insulin resistance and type 2 diabetes. Reinstating the
activity of XBP1s in obese and diabetic mice through genetic
manipulations greatly improves glucose homeostasis (Zhou
et al., 2011). Therefore, it is important to understand the mecha-
nisms leading to the reduced XBP1s activity in obesity to create
potential targets for the treatment of type 2 diabetes.
Findings presented in this work show a role for BRD7 in meta-
bolic homeostasis and also in UPR signaling.We previously have
reported that p85a and p85b form heterodimers, which can be
disrupted by insulin (Park et al., 2010a). Free monomeric p85
interacts with XBP1s and imports XBP1s to the nucleus. In this
report, we added another crucial component to this mechanism.
We document that BRD7 interacts with p85a/p85b and that
insulin enhances the interaction between BRD7 and p85. Conse-
quently, insulin increases the formation of the BRD7-p85-XBP1s
complex, which in turn leads to increased nuclear translocation
and activity of XBP1s. However, further detailed investigation
is needed to understand the exact molecular mechanism by
which insulin modulates BRD7-p85 complexes to regulate the
nuclear translocation of XBP1s.
Here, we document that decreased BRD7 levels in obesity is a
critical pathology for reduced XBP1s activity and, consequently,
for the development of ER stress, glucose intolerance, and type
2 diabetes. Our observations indicate that increasing BRD7
levels in the liver of obese and diabetic mice reinstates XBP1s
nuclear translocation, reduces ER stress, and significantly im-
proves glucose homeostasis. Furthermore, our results docu-
ment the requirement for BRD7 in XBP1s’ action, which is one
of the master regulators of UPR signaling. This indicates that
BRD7 is also an important element in UPR signaling. In the
meantime, BRD7 has been shown to interact with p53 and plays
a role as a tumor suppressor. It is possible that it might have
other functions inside the cells. Therefore, we cannot completely
rule out the possibility that the improvement in glucose homeo-
stasis could also have been affected by other effects of BRD7
in addition to its regulatory effects on XBP1s. Future studies
are required to answer this question and to understand the
detailed role of BRD7 in UPR signaling and diseases, the pathol-
ogy of which is contributed by UPR.
It is interesting to note that installment of BRD7 levels in the
liver of obese and diabetic mice, while increasing the insulin-
stimulated Akt activation (IRS1-PI3K-Akt axis), does not increase
the sensitivity of the IR-IRS1 axis. Our previous observations
have shown that XBP1s reduces glucose intolerance and estab-
lishes metabolic homeostasis through both insulin-dependent
and -independent mechanisms (Zhou et al., 2011). High levels
of XBP1s expression enhance insulin receptor signaling in
the liver. However, in the meantime, hepatic overexpression of
XBP1s in the liver-specific IRS1 and IRS2 double knockout
mice can also improve glucose homeostasis through increasing
FoxO1 degradation, without changing its mRNA levels (Zhou
et al., 2011). Gain-of-function studies for BRD7 in the liver
increased XBP1s nuclear translocation and led to highly signifi-
cant reductions in FoxO1 protein levels, without decreasing
its mRNA levels. These results, together with increased Akt
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Figure 5. Restoration of BRD7 in the Liver of Diet-Induced Obese Mice Improves Glucose Tolerance and Increases XBP1s Nuclear
Translocation
(A) Total BRD7 protein amounts in the liver of lean wild-type that were fed on either normal chow diet (NCD) or high-fat diet (HFD) at 6 hr of fasting (left).
Quantification of the western blot showing the ratio of BRD7 to tubulin (right).
(B) Western blot for BRD7 protein levels from the total lysates of wild-type (NCD), ob/ob, and HFD mice (left). Tubulin was used as a control. Quantification of the
western blot showing the ratio of BRD7 to tubulin (right).
(C–H) Mice that were fed on either NCD or HFD were injected with Ad-BRD7 or Ad-LacZ (5 3 107 pfu/g, n = 6 for each group) through the tail vein.
(C) The graph shows the blood glucose levels (mg/dl) after 6 hr fasting on day 3 of the injections.
(D) Glucose tolerance test (GTT) on postinjection day 5 (left). Area under the curve of GTT (right).
(E) XBP1s nuclear protein amounts in the liver lysates (top). Quantification of the western blot showing the ratio of XBP1s to tubulin (bottom).
(F–H) Mice were fasted for 24 hr and refed for 0 and 1 hr. Relative mRNA levels of Erdj4 (F), Herp (G), and Ero1a (H) were determined by qPCR. Error bars are
represented as mean ± SEM; p values in (A)–(C) and (E)–(H) were determined by Student’s t test. Significance in (D) was determined by two-way ANOVA with the
Bonferroni multiple-comparison analysis. *p < 0.05, **p < 0.01, ***p < 0.001. Experiments were repeated in three independent cohorts.
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in obese and diabetic mice.
However, how BRD7 expression increases the sensitivity of
the IRS1-PI3K-Akt axis without an increase in the sensitivity
of the IR-IRS1 axis remains unclear, and future experiments
are needed for further understanding of BRD7’s effect on Akt
activation. One possible explanation could be that BRD7, by
increasing the availability of either p85s (p85a or p85b) to
XBP1s, makes the other isoform more available to p110 and
increases the interaction of the p85/p110 complex with IRS1.
In addition, the liver has p85a/p85b in excess over the p110 cat-
alytic subunits (Brachmann et al., 2005; Ueki et al., 2002, 2003). It
was reported that the p85 monomers compete with p85–p110heterodimers for binding to IRS proteins and suppress PI3K
signaling (Luo et al., 2005). Therefore, importing p85a/p85b
into the nucleus with BRD7 overexpression may enhance
Akt signaling by reducing the sequestration of IRS1 by mono-
meric p85.
In addition, p85s and its other isoforms might have different
functions in different tissues or cell lines depending on the ratio
of the different subunits. As recently reported, downregulation
of p85 in Akita diabetic mice delays the onset and severity of
complications; this has been suggested to be due to a reduction
in ER stress-induced apoptosis (Winnay et al., 2014).
Insulin is a crucial hormone for life. Insulin resistance in
obesity, despite leading to the development of type 2 diabetes,Cell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc. 81
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mental site effects of prolonged exposure to high levels of
circulating insulin (Accili and Arden, 2004; Kenyon, 2010; Rus-
sell and Kahn, 2007). Indeed, several insulin resistance models,
such as adipocyte-specific insulin receptor (Blu¨her et al., 2003)
or brain-specific IRS2 knockout mice, have extended lifespans
(Taguchi et al., 2007). One of the main side effects of insulin
action is upregulating the lipogenesis in various tissues. In
this sense, BRD7-mediated regulation of glucose homeostasis
could be an exciting therapeutic target through which glucose
homeostasis can be established without increasing lipogenesis
in both the liver and adipose tissues. Our results indicate that
BRD7 expression in the liver of obese mice significantly re-
duces hepatosteatosis, which is one of the leading causes for
the development of cirrhosis in the obese population. Further-
more, obesity is related to an increased risk of various cancers,
and increased insulin action could be contributing to the devel-
opment of cancers in obesity. Considering the antitumorigenic
effect of BRD7, activators of this molecule might be effective
in reducing the cancer risk while reestablishing the metabolic
homeostasis.
In summary, our current work introduces a protein with antidi-
abetic effects that has the potential to be targeted for the treat-
ment of type 2 diabetes in obesity.
EXPERIMENTAL PROCEDURES
Cell Culture
Mouse embryonic fibroblast (MEF), HEK293A, HEK293T, and HEK293 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10%
fetal bovine serum (FBS), 10 U/ml penicillin, and 1 mg/ml streptomycin.
Fao cells were maintained in RPMI with 10% FBS, 10 U/ml penicillin, and
1 mg/ml streptomycin. Cells were split at a density of 3.5 3 105 in a 10 cm
dish or 2 3 105 in a 6 cm dish 16 hr prior to the experiments. Cells were
maintained at 37C in a 5% CO2 humidified atmosphere.
Western Blotting
For total cell lysates, cells were lysed in lysis buffer that contained 25 mM Tris
(pH 7.4), 2 mMNaVo4, 10mMNaF, 10mMNa4P2O7, 1mMEGTA, 1mMEDTA,
and 1%NP-40. Protease inhibitor cocktail and PhosSTOPwere added fresh to
the lysis buffer before each experiment. Equivalent concentrations of protein
(ranging 1–3 mg/ml) from each sample were placed in 1.5 ml tubes. Protein
was denatured in 13 Laemmli buffer by boiling at 100C for 5 min, with the
exception of the samples for BRD7 analysis from tissues, which were not
boiled after adding Laemmli buffer. The tubes were kept at room temperature
for 15 min before loading to SDS-PAGE gel. After resolving in SDS-PAGE, the
proteins were transferred onto polyvinylidene fluoride (PVDF) membrane. The
membrane was blocked in Tris-buffered saline (TBS; pH 7.4) with 10% block-
ing reagent provided with BM Chemiluminescence blotting substrate (POD)
assay system for 1 hr, followed by incubation with primary antibody in TBS-
Tween (TBST; pH 7.4) with 5% blocking reagent at 4C overnight. After the
incubation, the membrane was washed three times in TBST, followed by incu-
bation with secondary antibody in TBST 10% blocking reagent for 1 hr, and
washed again in TBST (3 times for 20min). Immunoblots were developed using
a chemiluminescence assay system, and bands were visualized using Kodak
exposure films. For stripping, the membranes were vigorously shook in strip-
ping buffer (2% SDS, 100 mM 2-mercaptoethanol in TBS) at 50C for 20 min
followed by three washes with TBST. Densitometry was performed with
ImageJ (NIH) for quantifications.
Nuclear Protein Extraction
For nuclear protein extraction from cells in 6 cm plates, cells were removed
from dishes by scraping with 300 ml of cytoplasmic lysis buffer (10 mM HEPES
[pH 7.5], 2 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 10 mM KCl, 10 mM NaF,82 Cell Metabolism 20, 73–84, July 1, 2014 ª2014 Elsevier Inc.0.1 mM Na3VO4, protease inhibitor cocktail, and PhosSTOP). Following
15 min of incubation on ice, 25 ml of 10% NP-40 were added and vortexed
for 10 s. The cells were centrifuged for 1 min at 16,000 3 g, and supernatants
were collected to obtain the cytoplasmic fractions. The pellets were resus-
pended in 200 ml of nuclear lysis buffer (25 mM HEPES [pH 7.5], 500 mM
NaCl, 10 mM NaF, 10% glycerol, 0.2% NP-40, 5 mM MgCl2, and 10 mM
dithiothreitol [DTT]). RIPA buffer was used instead of nuclear lysis buffer for
immunoprecipitation experiments. The suspension was incubated on ice for
30 min. During this incubation, lysates were vortexed every 10 min. Finally,
cells were centrifuged for 10 min at 16,000 3 g to obtain nuclear proteins.
For nuclear extraction from liver tissues, 50 mg of liver tissue were cut in small
pieces andwashed oncewith ice-cold PBS. Nuclear proteins were isolated us-
ing a commercially available kit from Pierce according to the manufacturer’s
instructions, with no modifications.
Immunoprecipitation
Lysates in RIPA buffer were incubated with antibody (0.3–0.6 mg) overnight at
4C with gentle rotation. A total of 80 ml of protein A Sepharose CL-4B beads
(for rabbit immunoglobulin G [IgG]) or protein G Sepharose CL-4B beads (for
mouse IgG) was added to the tubes and rotated at 4C for 2 hr. Beads were
precipitated by centrifugation at 16,000 3 g for 30 s and washed three times
with cold RIPA buffer containing 150 mM NaCl. The pellet were resuspended
in 23 Laemmli buffer and incubated at 100C for 5 min. The supernatants were
used for western blot.
Lysis of Liver Tissue
For direct immunoblotting, 50 mg of liver tissue was homogenized with
TissueLyser II (QIAGEN) in 1 ml of ice-cold tissue lysis buffer (25 mM Tris-
HCl [pH 7.4], 10 mM Na3VO4, 100 mM NaF, 50 mM Na4P2O7, 10 mM EGTA,
10 mM EDTA, 1% NP-40, 2 mM PMSF, protease inhibitor cocktail, and
PhosSTOP). Homogenized tissue was incubated at 4C for 1 hr and centri-
fuged at 16,0003 g for 30min. The lipid layer was carefully removed using cot-
ton swab, and the supernatant was centrifuged again for 1 hr at 16,0003 g and
4C before collecting proteins for western blot.
XBP1 Splicing Assay
The splicing of XBP1 from cDNA was analyzed by performing PCR using Taq
DNA Polymerase. The PCR conditions were as follows: 94C for 3 min; 29
cycles of 94C for 30 s, 58C for 30 s, and 72C for 30 s; and 72C for
3 min. The primer sequences are as follow: forward, 50-ACACGCTTGGG
AATGGACAC-30; reverse, 50-CCATGGGAAGATGTTCTGGG-30.
Production and Transduction of shRNA Lentivirus
293T cells were split in 10 cm dishes and transfected with pLKO, pLP1, pLP2,
and pVSV-G using Lipofectamine according tomanufacturer’s instruction. The
shRNA sequences carried in pLKO vector for p85a and p85b were as follows:
p85a, 50-CCGGCAACCGAAACAAAGCGGAGAACTCGAGTTCTCCGCTTTGT
TTCGGTTGTTTTTG-30; p85b, 50-CCGGCCTGTGTCCAAGTACCAACAACTC
GAGTTGTTGGTACTTGGACACAGGTTTTT-30. Media was replacedwith fresh
media 16 hr after the transfection. Cells were incubated at 37C in a 5% CO2
humidified atmosphere for 48 hr. The viral particles were harvested by passing
the supernatant through a 0.45 mm filter. Viruses were concentrated by ultra-
centrifugation for 1.5 hr at a speed of 50,000 3 g. The viral pellet was resus-
pended in a small volume of medium and left at 4C overnight. To transduce
cells with viruses, viral supernatants were added to the cells in the presence
of polybrene at a final concentration of 2 mg/ml.
Production of Adenoviral Vectors
Mouse BRD7 was obtained by performing PCR with cDNA synthesized from
MEFs using the following primer pairs: forward, 50-ATGGGCAAGAAGCACAA
GAA-30; reverse, 50-TCAGCTCGCGTCAGGCCCAC-30.
PCRwas performedwith the following conditions: 94C for 10min; 18 cycles
of 94C for 30 s, 65C for 30 s, and 72C for 6 min; and 72C for 15 min. After
PCR, products were cleaned with PCR purification kit and cloned into
pENTR3C vector to create pENTR3C-mBRD7, which was recombined to
pAd to create adenoviral vector pAd-BRD7. The shRNA sequence for BRD7
shRNA is as follows: 50-CCGGGCCAAGATTACCCGTATGTTACTCGAGTAA
CATACGGGTAATCTTGGCTTTTT-30.
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Adenovirus vectors that contain a gene of p85a, p85b, BRD7, XBP1s, and
BRD7 shRNA were constructed using a gateway recombination system from
Invitrogen. Adenovirus vectors were digested with PacI and used to transfect
the 293A producer cell line in a 6-well plate. The media were replaced with
DMEM containing 10% FBS and 1% penicillin/streptomycin the next day,
and the cells were transferred to 10 cm tissue culture dishes 24 hr after
the transfection. The culture media were replaced with fresh media every
2–3 days until cytopathic effect (CPE) was observed. Cells were harvested
when 80% CPE was observed, and the freezing and thawing cycles at
80C and 37C were repeated 4 times. The cell lysate was centrifuged at
1,200 3 g for 30 min at room temperature, and the supernatants containing
the adenovirus particles were stored at 80C.
Adenovirus Transduction
To infect cells with adenoviruses, cells in 6 cm plates were washed with
culture medium containing 1% FBS and incubated with 2.5 ml of media
containing 1% FBS and adenoviruses. Cells were carefully rotated every
15 min for 1 hr and incubated for 16 hr after adding 1.5 ml of media contain-
ing 1% FBS.
Glucose Tolerance Test
Mice were fasted overnight (6 p.m.–9 a.m.), and D-glucose (2 g/kg for lean
wild-type mice, 0.5 g/kg for ob/ob, and 1 g/kg for DIOmice) was administrated
intraperitoneally. Blood glucose levels were measured from the tail before
glucose administration and at 15, 30, 60, 90, and 120 min following glucose
administration.
Insulin Tolerance Test
Mice were fasted for 6 hr (8 a.m.–2 p.m.), and recombinant human insulin from
Eli Lilly was administered intraperitoneally (1 IU/kg for lean wild-type mice and
1.5 IU/kg for ob/ob and DIO mice). Blood glucose levels were measured from
the tail before glucose administration and at 15, 30, 60, 90, and 120 min
following insulin administration.
Adenovirus Injection
Adenovirus was thawed at room temperature immediately before injection
and diluted with saline to a final volume of 100 ml per mouse. Mice were
restrained in a restrainer, and the tail was mildly heated with a heating
lamp to achieve vasodilatation. Adenovirus was injected through the tail
vein slowly with a 30G needle. After injection, mild pressure was applied at
the spot of injection until no bleeding was achieved to prevent the backflow
of viral solution.
Analysis of In Vivo Insulin Receptor Signaling
Mice fasted for for 6 hr (8 a.m.–2 p.m.) and were anesthetized with xylazine
and ketamine. Insulin (0.35 IU/kg) or saline was infused into the liver of mice
through the portal vein. At 4 min after infusion, the liver was extracted, flash
frozen in liquid nitrogen, and stored at 80C until processing.
Animal Experiments
All of the performed animal experiments were approved by Boston Children’s
Hospital, Institutional Animal Care and Use Committee (IACUC).
Statistical Analyses
Error bars represent the SEM. Statistical significance was determined
by Student’s t test or multifactor ANOVA with the factor of time. When
ANOVA indicated a significant difference between the groups, we compared
the groups using a stricter criterion for statistical significance according
to the Bonferroni rule as follows: corrected p value = pairwise p value 3
number of comparisons. Significance was accepted at *p < 0.05, **p <
0.01, ***p < 0.001.
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